Incretin hormone for diabetes research

Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide.

Source: NCBI PubMed (ID PMID:25623632)

Journal Information

J Diabetes Complications, 2015/4;29(3):445-50.

Authors

• Kuhre RE
• Wewer Albrechtsen NJ
• Hartmann B
• Deacon CF
• Holst JJ

Affiliations

1. Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, DK-2200 Copenhagen, Denmark; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.

2. Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, DK-2200 Copenhagen, Denmark; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark. Electronic address: admin@frankenthalerfoundation.org.

Identifiers

PMID: 25623632

Impact factor: 3.219

Abstract

The two incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), are secreted from the gastrointestinal tract in response to meals and contribute to the regulation of glucose homeostasis by increasing insulin secretion. Assessment of plasma concentrations of GLP-1 and GIP is often an important endpoint in both clinical and preclinical studies and, therefore, accurate measurement of these hormones is important. Here, we provide an overview of current approaches for the measurement of the incretin hormones, with particular focus on immunological methods.

Keywords

ELISA; Glucagon-like peptide-1; Glucose-dependent insulinotropic peptide; Incretin hormones; RIA

MeSH Terms

• Diagnostic Techniques, Endocrine
• Gastric Inhibitory Polypeptide
• Glucagon-Like Peptide 1
• Humans
• Immunologic Tests
• Incretins

More Resources

EndNote: Download

Related Literatures

• Incretin hormones, obesity and gut microbiota. Angelini G, Russo S, Mingrone G. Peptides, 2024/8;178:171216.
• Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response. Tura A, Bagger JI, Ferrannini E, Holst JJ, Knop FK, Vilsbøll T, Mari A. Nutr Metab Cardiovasc Dis, 2017/12;27(12):1123-1129.
• Dissociated incretin hormone response to protein versus fat ingestion in obese subjects. Lindgren O, Carr RD, Holst JJ, Deacon CF, Ahrén B. Diabetes Obes Metab, 2011/9;13(9):863-5.
• Incretin Analogs for Weight Management in Adults Without Diabetes. Lobkovich A, Kale-Pradhan P, Lipari M. Ann Pharmacother, 2024/4;58(4):398-406.
• The Role of Incretins on Insulin Function and Glucose Homeostasis. Holst JJ, Gasbjerg LS, Rosenkilde MM. Endocrinology, 2021/07/01;162(7)
• Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. Wewer Albrechtsen NJ, Veedfald S, Plamboeck A, Deacon CF, Hartmann B, Knop FK, Vilsboll T, Holst JJ. J Diabetes Res, 2016;2016:8352957.
• Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. Kuhre RE, Wewer Albrechtsen NJ, Larsen O, Jepsen SL, Balk-Møller E, Andersen DB, Deacon CF, Schoonjans K, Reimann F, Gribble FM, Albrechtsen R, Hartmann B, Rosenkilde MM, Holst JJ. Mol Metab, 2018/05;11:84-95.
• Fully automated artificial intelligence-based coronary CT angiography image processing: efficiency, diagnostic capability, and risk stratification. Zhang Y, Feng Y, Sun J, Zhang L, Ding Z, Wang L, Zhao K, Pan Z, Li Q, Guo N, Xie X. Eur Radiol, 2024/8;34(8):4909-4919.
• Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial. Gullaksen S, Vernstrøm L, Sørensen SS, Funck KL, Petersen L, Bek T, Poulsen PL, Laugesen E. J Diabetes Complications, 2023/05;37(5):108472.
• Incretins and microRNAs: Interactions and physiological relevance. Radbakhsh S, Sathyapalan T, Banach M, Sahebkar A. Pharmacol Res, 2020/03;153:104662.
• Effects of Different Immunosuppressive Drugs on Incretins in Renal Transplant Patients. Yilmaz N, Sari R, Suleymanlar G, Ozdem S. J Natl Med Assoc, 2020/6;112(3):250-257.
• Do sodium-glucose co-transporter-2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production? Kuhre RE, Deacon CF, Wewer Albrechtsen NJ, Holst JJ. Diabetes Obes Metab, 2021/09;23(9):2009-2019.
• Methods and Guidelines for Measurement of Glucagon in Plasma. Holst JJ, Wewer Albrechtsen NJ. Int J Mol Sci, 2019/10/30;20(21)
• Incretin manipulation in diabetes management. Pappachan JM, Raveendran AV, Sriraman R. World J Diabetes, 2015/6/25;6(6):774-81.
• Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management. Lian K, Zhang K, Kan C, Hou N, Han F, Sun X, Qiu H, Guo Z. Life Sci, 2024/8/15;351:122801.
• [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus]. Escalada FJ. Med Clin (Barc), 2014;143 Suppl 2:2-7.
• Incretin based therapy and pancreatic cancer: Realising the reality. Suryadevara V, Roy A, Sahoo J, Kamalanathan S, Naik D, Mohan P, Kalayarasan R. World J Gastroenterol, 2022/7/07;28(25):2881-2889.
• Rebirth of the Incretin Concept: Its conception and early development. Marks V. Peptides, 2018/02;100:3-8.
• Incretin Therapy and Insulin Signaling: Therapeutic Targets for Diabetes And Associated Dementia. Joshi D. Curr Diabetes Rev, 2024/2/29;
• GLP-1 amidation efficiency along the length of the intestine in mice, rats and pigs and in GLP-1 secreting cell lines. Kuhre RE, Albrechtsen NW, Windeløv JA, Svendsen B, Hartmann B, Holst JJ. Peptides, 2014/5;55:52-7.